Xanthone Derivative Inhibits P-gp Efflux to Enhance Anticancer Drug Accumulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer drugs face challenges due to multidrug resistance in cancer cells, primarily attributed to the overexpression of P-glycoprotein (P-gp), which effluxes therapeutic drugs, reducing their concentration in cancer cells and leading to treatment failure, despite evidence that natural substances can modulate P-gp activity.
Innovation Solution
Development of a novel xanthone derivative or its pharmaceutically acceptable salt, specifically designed to inhibit P-gp activity, thereby enhancing the intracellular accumulation of anticancer drugs by preventing their efflux from cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If P-gp transport protein is overexpressed in cancer cells, then cellular efflux of toxic substances is enhanced, but concentration of therapeutic drug in cancer cells decreases leading to drug resistance
Solution Approach 1:
The patent uses P-gp inhibitors as intermediary substances that block the P-glycoprotein transport protein. These inhibitors act as mediators between the toxic substances and the cancer cells, preventing P-gp from effluxing therapeutic drugs while allowing the inhibitors to accumulate and exert their blocking effect on the transport protein function.
Solution Approach 2:
The patent changes the chemical structure parameters of xanthone compounds by introducing specific substituents (halogen atoms, hydroxyl groups, alkoxy groups at defined positions) to optimize the compound's ability to inhibit P-gp. This structural parameter modification enhances the inhibitory activity while maintaining selective accumulation in cancer cells.
2Reliability
If natural substances are used to modulate P-gp activity, then P-gp inhibition may be achieved, but selectivity between cancer cells and normal organs is reduced
Solution Approach 1:
The patent applies local quality by designing xanthone derivatives with specific substituent patterns (halogen at positions 5 or 8, hydroxyl at position 1, alkoxy groups at positions 3 and/or 5) that create localized chemical properties enhancing cancer cell selectivity. These specific structural modifications at particular positions on the xanthone core provide selective accumulation in cancer cells while sparing normal organs.
Solution Approach 2:
The patent creates composite molecular structures by combining the xanthone core framework with specific functional groups (halogen substituents, hydroxyl groups, alkoxy chains) to produce a composite compound with enhanced cancer-selective P-gp inhibition. This composite structure integrates multiple functional elements that work synergistically to achieve selectivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The xanthone derivative effectively reduces anticancer drug resistance by inhibiting P-gp activity, allowing higher concentrations of anticancer drugs to accumulate in cancer cells, thereby suppressing cancer growth and survival.
Implementation Method 1
P-gp is an ATP-dependent transport protein involved in cellular efflux of a wide variety of fat-soluble substances including anticancer drugs
Data Source
AI summary
The present invention provides a novel xanthone derivative compound or a pharmaceutically acceptable salt thereof. The compound is useful as a chemosensitizer that reduces anticancer drug resistance.